Medix Biochemica's PROM (premature rupture of foetal membranes) test:
This article was originally published in Clinica
Medix Biochemica's Actim PROM test is designed to rapidly detect the premature rupture of foetal membranes (PROM). The test has been marketed outside the US since 1995, and it was the first commercial test to recognise a protein highly specific for amniotic fluid, claimed the Kauniainen, Finland-based firm. This makes it less susceptible to common interfering factors that cause possible false positive or false negative results in other test methods, the company said. Last year, the firm won the first round in its legal wrangle with US company N-Dia concerning the infringement of patents related to diagnostic methods and test kits for detecting PROM (see Clinica No 1208 p 13).
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.